

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. -8. (canceled).

9. (currently amended): A method for measuring an occupying ratio of a compound

1. bound to an epitope region recognized by antibodies 45531.111 and 45523.111 of strong binding site of CCR5 on a CCR5 expressing cell or a membrane fraction thereof, which comprises and

2. having a ligand binding inhibitory effect after 6 to 10 washings, said method comprising:

(a) allowing a CCR5 expressing cell or a membrane fraction thereof to contact with a compound to be tested,

(b) allowing the test compound-bound cell or a membrane fraction thereof prepared in the above step (a) to contact with a labeled ~~anti-CCR5~~45531.111 or 45523.111 antibody, ~~wherein when an antagonist or an agonist is bound to the strong binding site of CCR5, the antibody has a property of not binding to CCR5, or an isotype control of the labeled anti-CCR5 antibody or a~~
labeled isotype control of the 45531.111 or 45523.111 antibody, and

(c) calculating an occupying ratio of the compound bound to the epitope region recognized by the antibodies 45531.111 and 45523.111~~strong binding site of CCR5 on the cell or~~
membrane fraction thereof, based on the ratio of:

a bound amount of ~~the anti-CCR5~~45531.111 or 45523.111 antibody when the compound is bound to CCR5 corrected by using the labeled isotype control to

a bound amount of ~~the anti-CCR5~~45531.111 or 45523.111 antibody when the compound is not bound to CCR5 corrected by using the labeled isotype control, which is defined as 100%.

10.-33. (canceled).

34. (new): The method according to claim 9, wherein the compound has an IC50 values of 1.5 nmo/l to 4.2 nmo/l for the ligand binding inhibitory activity after being subjected to 8 washings.

35. (new): The method according to claim 9, wherein the compound has a strong ligand binding inhibitory effect after being subjected to 8 washings.